Typical or atypical pneumonia and severe acute respiratory symptoms in PICU

Kam Lun Hon1, Agnes S Y Leung1, Kam Lau Cheung1

  • 1Departments of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.

Abstract

Insights

Mycoplasma pneumoniae (MP) can cause severe atypical pneumonia (AP) requiring pediatric intensive care (PICU). While rare, severe MP cases highlight the need for clear diagnostic criteria and management strategies for pediatric respiratory infections.

Area of Science:

  • Pediatric Infectious Diseases
  • Respiratory Medicine
  • Critical Care Medicine

Background:

  • Mycoplasma pneumoniae (MP) is a common childhood pathogen causing atypical pneumonia (AP).
  • Severe presentations of AP, particularly those requiring pediatric intensive care (PICU), are uncommon.
  • Outbreaks of severe respiratory illnesses have led to the creation of various, sometimes confusing, terminologies like SARS, MERS, and SARI.

Observation:

  • A case of an 11-year-old girl with severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), pneumonia, and pleural effusion is presented.
  • MP was identified as the causative agent, despite initial presentation mimicking typical pneumonia.
  • The patient's respiratory status indicated severe lung injury, necessitating PICU admission.

Findings:

  • Literature review indicates that severe AP requiring PICU admission due to MP is rarely reported, with generally low mortality.
  • The pathogenesis of lung injury in MP infection involves a cell-mediated immune response.
  • Severe MP cases may respond well to corticosteroid therapy, alongside general cardiopulmonary support and antimicrobial treatment.

Implications:

  • This case underscores the importance of considering MP in severe pediatric pneumonia, even with atypical presentations.
  • Standardized diagnostic approaches and clear terminology are crucial for managing severe respiratory infections.
  • Further research into MP pathogenesis and treatment, including macrolide resistance, is warranted for optimizing patient outcomes.

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
84
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.5K
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
24
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
4.7K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.4K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K